Mycobacterium Tuberculosis-Associated Hemophagocytic Syndrome in Systemic Lupus Erythematosus: A Case Report
Hussein HALABI, 1 Waleed HAFIZ, 1 Mayadah BAWAYAN, 1 Abdulghani MAULAWI, 2 Hani ALMOALLIM3
1King Faisal Specialist Hospital and Research Center, Medicine, Jeddah, Suudi Arabistan
2King Faisal Specialist Hospital and Research Center, Pathology, Jeddah, Suudi Arabistan
3Umm Al Qura University, Medicine, Makkah, Suudi Arabistan
Keywords: Hemophagocytic syndrome; systemic lupus erythematosus; tuberculosis
Mycobacterium tuberculosis infection is a complex, potentially life-threatening disease. Multiple hematological abnormalities may be seen in tuberculosis infection. However, Mycobacterium tuberculosis-associated hemophagocytic syndrome (HPS) in systemic lupus erythematosus (SLE) patients is quite rare. In this article, we report a 47-year-old female case of Mycobacterium tuberculosis-associated HPS in a patient with SLE. The patient had diffuse alveolar hemorrhage, myocarditis, and acute renal failure and required 17 sessions of plasma exchange and six sessions of cyclophosphamide. She also presented with fever, hypotension, desaturation, hepatosplenomegally, and pancytopenia which required intubation. Broncho-alveolar lavage revealed the diagnosis of Mycobacterium tuberculosis. The patient was initiated with rifampicin, ethambutol, pyrazinamide, moxifloxacin and amikacin. There was no indication of any SLE flare; however she continued to be febrile and pancytopenic. Her ferritin level was observed to be elevated. A bone marrow examination also showed hemophagocytosis plus multiple granulomas. Despite active treatment, the patient died due to septic shock and multi-organ failure. Mycobacterium tuberculosis has the potential to induce HPS in SLE patients; therefore, accurate diagnosis and aggressive therapy are critical. All SLE patients should be screened for latent tuberculosis and managed accordingly.
Hemophagocytic syndrome (HPS) is a hematological phenomenon characterized by the activation of either macrophages or histiocytes that contain prominent hemophagocytosis features in the bone marrow and other reticulo-endothelial systems. This leads to the phagocytosis of white blood cells, red blood cells, platelets, and their precursors. Infections, malignancies, autoimmune diseases, and a variety of other medical conditions can all lead to HPS.
In systemic lupus erythematosus (SLE) patients, HPS associated with Mycobacterium tuberculosis has only been reported once. Herein, we report a case of an SLE patient who developed HPS due to this type of bacteria.
A 47-year-old female was diagnosed with a case of SLE in November 2009 when she first presented with constitutional symptoms, a malar rash, and pancytopenia [white blood cell count 3x10^9 (3.9-11x10^9), hemoglobin 8.5 g/l (11-16 g/l), platelet 39x10^9 (150- 400x10^9)] along with positive antinuclear antibody (ANA), and anti-double-stranded DNA (anti-ds-DNA) antibodies. Her temperature was 36.9 °C, and her blood pressure was 74/45 mmHg. Furthermore, her heart rate was 108 beats/minute, and her respiratory rate was 20 breaths/minute. A chest examination revealed coarse crackles throughout both lungs as well as central and bilateral lung infiltration. The cardiac, abdominal, and neuromuscular exams were unremarkable. The patient was admitted to the intensive care unit (ICU) with diffuse alveolar hemorrhage and was started on pulse methylprednisolone, plasma exchange, and cyclophosphamide. She was also found to have severe mitral valve regurgitation, diffuse myocardial wall suppression, an ejection fraction of 25%, and acute renal failure and received a total of 17 sessions of plasma exchange, three cycles of cyclophosphamide, and several sessions of hemodialysis. After this treatment in December 2009, her ejection fraction improved to 55%, and her mitral valve regurgitation was found to be mild. She then underwent a renal biopsy that showed lupus nephritis class II (mesangial proliferation with mild-to-moderate fibrosis). She was also to complete a total of six cycles of cyclophosphamide every other week.
In February 2010, just a few hours after finishing her last cycle of cyclophosphamide, the patient came to the emergency department complaining of fever and lethargy. Her physical examination revealed an oral temperature of 38.4 °C, blood pressure of 80/50 mmHg, heart rate of 110 beats/ min, respiratory rate of 18 breaths/min, and oxygen saturation of 96% at room air. Chest auscultation revealed coarse crackles, and abdominal palpation was notable for hepatosplenomegaly, which had not been found during her previous admission. She was resuscitated with intravenous fluids and started on broad-spectrum antibiotics plus hydrocortisone. Laboratory investigation showed the following: hemoglobin 10.5 g/l (normal range 11-16 g/l), white blood cell count 1.48x10^9 (normal range 3.9-11x10^9) with neutrophils at 71%, lymphocytes at 17%, and monocytes at 6%, platelet count 58x10^9 (normal range 140-350 x 10^9), lactate dehydrogenase 994 U/l (normal range 135-214 U/l), C-reactive protein (CRP) 273 mg/l (normal range 0-5 mg/l), erythrocyte sedimentation rate (ESR) 55 mm/hr (normal range <15 mm/hr), lactic acid 4.1 mmol/l (normal range 0.5-2 mmol/l), alanine aminotransferase 147 U/l (normal range 10-45 U/l), and aspartate aminotransferase 87 U/l (normal range 10-45 U/l). The electrolytes and urea were normal. A chest X-ray showed widespread bilateral fine nodular shadows, but the patient had no symptoms and signs that indicated an SLE flare-up. Her C3 was 1.05 g/l (normal range 0.9-1.8 g/l), and her C4 was 0.83 g/l (normal range 0.1-0.4 g/l). In addition, the patient's anti-ds-DNA antibody titer was normal.
She was admitted to the ward after resuscitation. Thoracic computed tomography (CT) showed diffuse bilateral centrilobular lung nodules, paraaortic lymph node enlargement, and a small splenic lesion. By the next morning, the patient began to desaturate and required intubation. She was then moved to the ICU where she underwent a bronchoscopy, and a bronchoalveolar lavage sample was positive for acid-fast bacillus. The diagnosis of Mycobacterium tuberculosis infection was made, and she was started on rifampicin, ethambutol, pyrazinamide, moxifloxacin, and amikacin. All other cultures (blood and urine) were negative. Tests for brucella titer and hepatitis B and C were negative, and viral serology for cytomegalovirus (CMV), Epstein- Barr virus (EBV), and human immunodeficiency virus (HIV) also came back negative. Additionally, her fungal culture was also negative.
The patient, however, continued to be febrile and pancytopenic, and a suspicion of HPS was raised due to a ferritin level of 6.800 ug/l (normal range 15-150 ug/l). The patient underwent a bone marrow biopsy and aspiration which showed that her cellular marrow was infiltrated with abnormal histiocytes plus multiple granuloma consistent with hemophagocytosis (Figures 1 and 2). Therefore, HPS associated with Mycobacterium tuberculosis was diagnosed. Although she was on antituberculous medication and broadspectrum antibiotics, the patient developed septic shock and multi-organ failure which resulted in her death.
Although rare, HPS can occur in both active and inactive cases of SLE, but the majority take place during active SLE. Most instances of HPS in inactive SLE are thought to be related to immunosuppressive drugs,[3,4] and several viral, bacterial, fungal, and parasitic infections have also been found to be associated with HPS.
Hemophagocytic syndrome is a potentially life-threatening, aggressive disease that manifests clinically with fever, lymphadenopathy, jaundice, hepatosplenomegaly, and bleeding tendency. Laboratory tests may show pancytopenia, elevated ferritin and lactate dehydrogenase levels, and disseminated intravascular coagulopathy (DIC). Diagnosis is confirmed by a bone marrow biopsy that shows hemophagocytosis. The mechanism of HPS is not well known. The immune complex deposits hematopoietic cells on the bone marrow and produces autoantibodies. These autoantibodies react with the hematopoietic cells, and then the histiocytes phagocytose these cells. Interleukin-1 (IL-1), tissue necrosis factors-α (TNF-α) and interferon-γ (INF-γ) are reported to be important for histiocyte activation and the pathogenesis of HPS.[5,6] When HPS is a manifestation of SLE, it is treated with high-dose corticosteroids. In one patient with SLE, plasma exchange was used for treatment of HPS. In addition, pathogen-directed therapy is indicated in HPS cases caused by infection.[4,5]
In patients with SLE, two cases of mycobacteria have been reported that were associated with HPS. The first case was a 15-year-old girl with SLE who was diagnosed with HPS associated with Mycobacterium avium complex (MAC). Her SLE was inactive, and she responded poorly to initial treatment with corticosteroids and intravenous immunoglobulins. However, following treatment with clarithromycin, amikacin, and ciprofloxacin, she improved gradually and was discharged. The second case, a 36-year-old woman, was initially thought to have acute lupus hemophagocytic syndrome. However, increased levels of CRP led to further investigation. A Ziehl-Neelsen stain of the buffy coat showed acid-fast bacilli in the phagocytic cells, and the diagnosis of HPS associated with Mycobacterium tuberculosis was confirmed by blood cultures and polymerase chain reaction. She died despite active treatment. Our case is the second case of HPS in inactive SLE caused by Mycobacterium tuberculosis. Our patient's characteristics were compared to the characteristics of the two patients in the preceding cases and are presented in Table 1.
As our case and a review of the literature demonstrate, HPS in SLE is an aggressive disease regarding both flare-ups and conditions related to infection. Mycobacterium tuberculosis should be considered in the differential diagnosis of the organisms that can cause HPS in SLE. We recommend that any SLE patient should be examined for the presence of latent Mycobacterium tuberculosis prior to initiating immunosuppressive therapy, especially in endemic areas. In one study, it was found that the use of isoniazid prophylaxis in such patients decreased the incidence of tuberculosis from 11% to2 %. The published literature suggests that T-cell interferon-gamma release assays (IGRAs) have a better diagnostic sensitivity to diagnose latent Mycobacterium tuberculosis than tuberculin skin testing (TST) in patients with immune-mediated inflammatory diseases. Once confirmed, accurate treatment should be strongly considered.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.
- Botelho C, Ferrer F, Francisco L, Maia P, Mendes T, Carreira A. Acute lupus hemophagocytic syndrome: report of a case. Nefrologia 2010;30:247-51. doi: 10.3265/ Nefrologia.pre2009.Dic.5499.
- Au WY, Kwong YL, Yuen KY. Hemophagocytosis in the peripheral blood due to tuberculosis mycobacteremia. Am J Med 2005;118:1298-9.
- Okada M, Suzuki K, Hidaka T, Shinohara T, Kataharada K, Matsumoto M, et al. Hemophagocytic syndrome in systemic lupus erythematosus. Intern Med 2001;40:1263-4.
- Papo T, Andre MH, Amoura Z, Lortholary O, Tribout B, Guillevin L, et al. The spectrum of reactive hemophagocytic syndrome in systemic lupus erythematosus. J Rheumatol 1999;26:927-30.
- Yang WK, Fu LS, Lan JL, Shen GH, Chou G, Tseng CF, et al. Mycobacterium avium complex-associated hemophagocytic syndrome in systemic lupus erythematosus patient: report of one case. Lupus 2003;12:312-6.
- Takahashi K, Kumakura S, Ishikura H, Murakawa Y, Yamauchi Y, Kobayashi S. Reactive hemophagocytosis in systemic lupus erythematosus. Intern Med 1998;37:550-3.
- Aoki A, Hagiwara E, Ohno S, Ueda A, Tsuji T, Ideguchi H, et al. Case report of systemic lupus erythematosus patient with hemophagocytic syndrome, treated with plasma exchange, with specific reference to clinical profile and serum cytokine levels. Ryumachi 2001;41:945-50. [Abstract]
- Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002;61:251-3.
- Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-52.